LTZ Therapeutics received FDA clearance for an IND covering LTZ-232, allowing the company to start a Phase 1 study in patients with advanced metastatic colorectal cancer and other solid tumors. LTZ-232 is positioned as the company’s next clinical step following the agency’s approval to begin human testing. The initiation broadens LTZ Therapeutics’ presence in oncology early-phase development and moves the program into a setting where safety, dose escalation and preliminary activity will be assessed across specified solid tumor populations. For investors and partners, the IND clearance reduces early execution friction and brings the molecule closer to generating trial data that can support later development decisions.